Charles River Laboratories International (NYSE:CRL) Updates FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 11.150-11.450 for the period, compared to the consensus EPS estimate of 11.090. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.8 billion.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Mizuho upped their price target on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Morgan Stanley reiterated an “overweight” rating and set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Friday. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $246.69.

Charles River Laboratories International Price Performance

CRL traded down $3.39 during trading on Friday, reaching $262.12. The company’s stock had a trading volume of 286,080 shares, compared to its average volume of 922,023. The company has a market cap of $12.63 billion, a price-to-earnings ratio of -54.06, a PEG ratio of 2.86 and a beta of 1.38. The firm has a fifty day simple moving average of $213.14 and a two-hundred day simple moving average of $188.71. Charles River Laboratories International has a 1 year low of $144.26 and a 1 year high of $268.00. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the business earned $3.12 earnings per share. The business’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts anticipate that Charles River Laboratories International will post 11.23 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,264,241. The trade was a 51.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently made changes to their positions in the company. Compound Planning Inc. lifted its holdings in Charles River Laboratories International by 19.6% in the fourth quarter. Compound Planning Inc. now owns 1,668 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 273 shares during the last quarter. Invesco Ltd. increased its stake in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Corient Private Wealth LLC raised its position in Charles River Laboratories International by 236.2% in the fourth quarter. Corient Private Wealth LLC now owns 35,170 shares of the medical research company’s stock valued at $7,016,000 after purchasing an additional 24,708 shares during the period. Mercer Global Advisors Inc. ADV raised its position in Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after purchasing an additional 80 shares during the period. Finally, State of Tennessee Department of Treasury lifted its stake in shares of Charles River Laboratories International by 32.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 12,593 shares of the medical research company’s stock valued at $2,651,000 after purchasing an additional 3,104 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.